(Q35925570)

11 August 2017

1 reference

title

Lipid-lowering therapies in development (English)

1 reference

11 August 2017

1

Anthony S Wierzbicki

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Investigational Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

13

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

1405-1418

1 reference

Systematic review on the risk and benefit of different cholesterol-lowering interventions

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

The lipid and non-lipid effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Beyond LDL-C--the importance of raising HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Statin-fibrate combination: therapy for hyperlipidemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Rosuvastatin for the treatment of patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Dangers of rosuvastatin identified before and after FDA approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

NK-104: a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

RETRACTED: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Ezetimibe for management of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Profiling of hepatic gene expression in rats treated with fibric acid analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

The safety and immunogenicity of a CETP vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

High density lipoprotein, apolipoprotein A-I, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

HDL therapy for the acute treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Apolipoprotein A-I(Milano): current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Oxidized LDL and HDL: antagonists in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

A synthetic peptide that inhibits lipoprotein(a) assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Effects of AGI-1067 and probucol after percutaneous coronary interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

A strategy to reduce cardiovascular disease by more than 80%

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1405

10.1517/13543784.13.11.1405

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference